{"id":"https://openalex.org/W7225731450","doi":"https://doi.org/10.25251/vg36kz58","title":"Real-world Treatment Persistence of Lebrikizumab by Atopic Comorbidity Among Patients with Moderate-to-severe Atopic Dermatitis in the US","display_name":"Real-world Treatment Persistence of Lebrikizumab by Atopic Comorbidity Among Patients with Moderate-to-severe Atopic Dermatitis in the US","publication_year":2026,"publication_date":"2026-11-10","ids":{"openalex":"https://openalex.org/W7225731450","doi":"https://doi.org/10.25251/vg36kz58"},"language":"en","primary_location":{"id":"doi:10.25251/vg36kz58","doi":"https://doi.org/10.25251/vg36kz58","is_oa":true,"landing_page_url":"https://doi.org/10.25251/vg36kz58","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://doi.org/10.25251/vg36kz58","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5070925575","display_name":"Shawn G. Kwatra","orcid":"https://orcid.org/0000-0003-3736-1515","observed_orcids":["https://orcid.org/0000-0003-3736-1515"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shawn Kwatra","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043201259","display_name":"Peter Lio","orcid":"https://orcid.org/0000-0001-7600-0152","observed_orcids":["https://orcid.org/0000-0001-7600-0152"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Peter Lio","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001401093","display_name":"Jenny E. Murase","orcid":"https://orcid.org/0000-0002-7529-9778","observed_orcids":["https://orcid.org/0000-0002-7529-9778"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jenny E Murase","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047569732","display_name":"Sharanya Murty","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sharanya Murty","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112881297","display_name":"M Molaei","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Matt Molaei","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5092114320","display_name":"Elsa Inman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Elsa Inman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5081642726","display_name":"Evangeline J. Pierce","orcid":"https://orcid.org/0000-0002-8287-2835","observed_orcids":["https://orcid.org/0000-0002-8287-2835"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Evangeline Pierce","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"10","issue":"6","first_page":"s900","last_page":"s900"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.9771000146865845,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.9771000146865845,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11620","display_name":"Medication Adherence and Compliance","score":0.004399999976158142,"subfield":{"id":"https://openalex.org/subfields/2714","display_name":"Family Practice"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10051","display_name":"Asthma and respiratory diseases","score":0.0027000000700354576,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8647000193595886},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.8479999899864197},{"id":"https://openalex.org/C2779159551","wikidata":"https://www.wikidata.org/wiki/Q1414874","display_name":"Comorbidity","level":2,"score":0.8327999711036682},{"id":"https://openalex.org/C2781009140","wikidata":"https://www.wikidata.org/wiki/Q7170389","display_name":"Persistence (discontinuity)","level":2,"score":0.7782999873161316},{"id":"https://openalex.org/C2778329239","wikidata":"https://www.wikidata.org/wiki/Q268667","display_name":"Atopic dermatitis","level":2,"score":0.6822999715805054},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.41929998993873596},{"id":"https://openalex.org/C2776042228","wikidata":"https://www.wikidata.org/wiki/Q35869","display_name":"Asthma","level":2,"score":0.41659998893737793},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.38179999589920044},{"id":"https://openalex.org/C104863432","wikidata":"https://www.wikidata.org/wiki/Q614304","display_name":"Pharmacy","level":2,"score":0.3799000084400177},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.34360000491142273},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.3400000035762787},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.335099995136261},{"id":"https://openalex.org/C207480886","wikidata":"https://www.wikidata.org/wiki/Q42982","display_name":"Allergy","level":2,"score":0.3158999979496002},{"id":"https://openalex.org/C205545832","wikidata":"https://www.wikidata.org/wiki/Q17156455","display_name":"Young adult","level":2,"score":0.29919999837875366},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.2847999930381775},{"id":"https://openalex.org/C185926286","wikidata":"https://www.wikidata.org/wiki/Q1929812","display_name":"Systemic therapy","level":4,"score":0.28349998593330383},{"id":"https://openalex.org/C2779824493","wikidata":"https://www.wikidata.org/wiki/Q5315925","display_name":"Dupilumab","level":3,"score":0.28290000557899475},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.2734000086784363},{"id":"https://openalex.org/C500440147","wikidata":"https://www.wikidata.org/wiki/Q701216","display_name":"Pharmacotherapy","level":2,"score":0.26829999685287476}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.25251/vg36kz58","doi":"https://doi.org/10.25251/vg36kz58","is_oa":true,"landing_page_url":"https://doi.org/10.25251/vg36kz58","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.25251/vg36kz58","doi":"https://doi.org/10.25251/vg36kz58","is_oa":true,"landing_page_url":"https://doi.org/10.25251/vg36kz58","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"},"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":[],"abstract_inverted_index":{"Introduction:":[0],"Lebrikizumab,":[1],"a":[2,86,139,187,190],"monoclonal":[3],"antibody":[4],"selectively":[5],"targeting":[6],"interleukin-13,":[7],"is":[8],"an":[9,52,114],"approved":[10],"therapy":[11,97,116,217],"for":[12,170,186],"atopic":[13,26,321],"dermatitis":[14],"(AD).":[15],"This":[16,33],"study":[17,35],"evaluated":[18],"the":[19,41,56,102,109,194],"relationship":[20],"between":[21,69,131],"real-world":[22,135,303],"treatment":[23,127],"persistence":[24,247,315],"and":[25,85,99,172,213,237,290],"comorbidity":[27,162,229,322],"status":[28],"among":[29,268,291],"lebrikizumab":[30,66,83,121,205,305],"initiators.":[31],"Methods:":[32],"retrospective":[34],"analyzed":[36,200],"secondary":[37],"claims":[38],"data":[39],"from":[40],"IQVIA":[42],"PharMetrics":[43],"dataset.":[44],"Eligible":[45],"participants":[46,147,269],"were":[47,159,199,208,294],"aged":[48],"\u226512":[49,76],"years,":[50,210],"had":[51,75,222,227,240],"AD":[53],"diagnosis":[54],"in":[55,101,141,307],"pre-index":[57,80,103,196],"period":[58],"(12":[59],"months":[60,77,119,152],"prior":[61,94,325],"to":[62,113],"index":[63],"fill),":[64],"initiated":[65,306],"(\u22651":[67],"fill)":[68],"October":[70],"1,":[71],"2024\u2013July":[72],"31,":[73],"2025,":[74],"of":[78,111,120,146,180,274,320],"continuous":[79],"enrollment":[81],"without":[82,272,311],"dispensing,":[84],"\u22656-month":[87],"follow-up.":[88],"Baseline":[89],"characteristics":[90],"identified":[91],"included":[92],"demographics,":[93],"advanced":[95,215],"systemic":[96,216],"experience,":[98],"comorbidities":[100,273,312],"period.":[104],"Persistence":[105,143,263],"was":[106,249,264,317],"defined":[107],"as":[108,175,177],"absence":[110],"switching":[112],"alternative":[115],"within":[117],"six":[118,151,244],"initiation":[122],"rather":[123,137],"than":[124,138],"discontinuation":[125],"(a":[126],"gap).":[128],"Longer":[129],"gaps":[130],"fills":[132],"may":[133],"reflect":[134],"dosing":[136],"lapse":[140],"therapy.":[142],"rates":[144],"(proportion":[145],"who":[148,156,293],"switched":[149],"at":[150],"post-index":[153],"vs.":[154],"those":[155],"did":[157],"not)":[158],"reported":[160],"across":[161,251],"burden":[163,323],"categories":[164],"(no":[165],"comorbidity,":[166],"\u22651,":[167],"\u22652),":[168],"specifically":[169],"asthma":[171],"allergic":[173,233,282,287],"rhinitis,":[174],"well":[176],"bio-experience":[178],"(evidence":[179],"\u22651":[181,228,257],"pharmacy":[182],"or":[183,189,271,310,324],"medical-benefit":[184],"claim":[185],"biologic":[188,326],"JAK":[191],"inhibitor":[192],"during":[193],"12-month":[195],"period).":[197],"Data":[198],"descriptively.":[201],"Results:":[202],"Among":[203],"355":[204],"initiators,":[206],"38.6%":[207],"18-44":[209],"56.9%":[211],"female,":[212],"68.7%":[214],"experienced.":[218],"Overall,":[219],"63.9%":[220],"(227/355)":[221],"no":[223,254,279,286],"comorbidities,":[224],"36.1%":[225],"(128/355)":[226],"(asthma:":[230,276],"21.7%":[231],"(77/355);":[232],"rhinitis:":[234,283,288],"20.3%":[235],"(72/355)),":[236],"14.1%":[238],"(50/355)":[239],"\u22652":[241,260],"comorbidities.":[242],"At":[243],"months,":[245],"overall":[246],"(83.1%)":[248],"consistent":[250,318],"groups:":[252],"AD,":[253],"comorbidities:":[255,261],"84.1%;":[256],"comorbidity:":[258],"81.3%;":[259],"82.0%.":[262],"also":[265],"numerically":[266],"similar":[267],"with":[270,309],"interest":[275],"84.4%":[277],"versus":[278,285,297],"asthma:":[280],"82.7%;":[281],"81.9%":[284],"83.4%)":[289],"patients":[292,308],"bio-experienced":[295],"(81.6%)":[296],"bio-na\u00efve":[298],"(86.5%).":[299],"Conclusions:":[300],"In":[301],"this":[302],"study,":[304],"demonstrated":[313],"six-month":[314],"that":[316],"regardless":[319],"use.":[327]},"counts_by_year":[],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2026-11-11T00:00:00"}